SCHEMBL26008244

SCHEMBL26008244

N[C@@H](Cc1ccc(CNC(=O)N2CCN(CC(=O)O)CC2)cc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.51
▸ TPSAB1 Q15661 6/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ SLC7A5 Q01650 2/20 0.44
▸ HRH3 Q9Y5N1 2/20 0.44
▸ ALPI P09923 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ XIAP P98170 1/20 0.43
▸ PRSS1 P07477 2/20 0.42
▸ TPSD1 Q9BZJ3 2/20 0.42
▸ TPSG1 Q9NRR2 2/20 0.42
▸ NOS3 P29474 1/20 0.42
▸ NOS1 P29475 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MLLT1 Q03111 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25356954 1.00 KDM4E (0.51) KDM4ETPSAB1MEN1KMT2ASLC7A5
SCHEMBL26009757 1.00 KDM4E (0.51) KDM4ETPSAB1MEN1KMT2ASLC7A5
SCHEMBL26009187 0.92 KDM4E (0.53) KDM4ETPSAB1MEN1KMT2ASLC7A5
SCHEMBL26008256 0.92 KDM4E (0.53) KDM4ETPSAB1MEN1KMT2ASLC7A5
SCHEMBL25357301 0.89 KDM4E (0.50) KDM4ETPSAB1MEN1KMT2ASLC7A5
SCHEMBL26009753 0.89 KDM4E (0.50) KDM4ETPSAB1MEN1KMT2ASLC7A5
SCHEMBL25360874 0.83 ITGB3 (0.49) SLC7A5
SCHEMBL31688659 0.83 ITGB3 (0.49) SLC7A5
SCHEMBL26009739 0.83 ITGB3 (0.49) SLC7A5
SCHEMBL25356716 0.83 KDM4E (0.52) KDM4ETPSAB1MEN1KMT2AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 — — EP disclosed
EP-4724459-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Peptidream Inc (JP) 2026-04-15 — — EP disclosed
WO-2024254339-A9 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2025-10-16 — — WO disclosed
WO-2024254339-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF RAYZEBIO, INC. (US) 2024-12-12 — — WO disclosed
WO-2024252336-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF PEPTIDREAM INC. (JP) 2024-12-12 — — WO disclosed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 — — US disclosed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP KDM4E 4463/4885TPSAB1 2973/4885MEN1 1901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback